Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced HER2+Breast Cancer
Interventions: DRUG: Alpelisib|DRUG: Alpelisib matching Placebo|DRUG: Trastuzumab|DRUG: Pertuzumab
Sponsor: Novartis Pharmaceuticals